IAM
ALXN

Iridian Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Iridian Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,200
Closed -$313K – 90
2019
Q3 		$313K Buy
+3,200
New +$361K ﹤0.01% 70

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Iridian Asset Management's ALXN Position: Q1 2021 in Review

Iridian Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 656,409 shares — an estimated $103M sold.

Iridian Asset Management first reported a position in ALXN in Q1 2018 and held it in 12 quarters. The position peaked at $329M in Q3 2018. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Iridian Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Iridian Asset Management sold 656,409 Alexion Pharmaceuticals shares in Q1 2021, an estimated $103M.
  • Iridian Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 12 quarters.
  • Iridian Asset Management's Alexion Pharmaceuticals position peaked at $329M in Q3 2018.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Iridian Asset Management's 13F filing for Q1 2021, filed 11 May 2021.